Mangoceuticals, Inc. focuses on develops, markets, and sells various men's wellness products and services through a telemedicine platform. It offers erectile dysfunction products under the Mango brand name. The company sells its products through online website mangorx.com. Mangoceuticals, Inc. was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.

Mangoceuticals, Inc.

Healthcare

The company does not pay dividends at all, or it pays them sporadically. There have only been a few years with dividend payments in the past ten years. 

Over the past six months, the stock has consistently fallen, resulting in a 25% total decrease. When measured against its worldwide peers from the same industry (as shown above), the stock has been weaker, underperforming by 17ppts. This is equally valid for peers from the same country and industry. Given the stock's valuation versus its peers, its total price movement is slightly unfavourable.

The company has reported very poor EBITDA margins compared to its global peers in recent years. EBITDA margin amounted to -1292.8% in the last 12 months, a decline from -1255.8% in FY23. 

Historically, MGRX has reported very poor net margins compared to its global peers. Specifically, in the last 12 months, this metric equalled -1413.6%, down from -1259.4% in FY23. 

Mangoceuticals, Inc. reported a return on equity (RoE) of -118.3% in the last 12 months, up from -1326.7% in FY23. 

Another important profitability metric, return on assets (RoA), amounted to -106.0% in the last 12 months, an increase from -897.0% in FY23. 

In the last 12 months, the return on capital employed (RoCE) grew to -117.8%, below the peers. 

The ratio of return on invested capital (RoIC) to the weighted average cost of capital (WACC) has been -30.4 in the past several years. This ratio implies a fragile shareholder value creation. 

The institutional, legal, and compliance risks associated with the company's country are minimal. In combination with stringent business standards, shareholder rights are very highly protected.

MGRX has very poor trading liquidity. The average private investor can sell his common position in the stock in a single trading day. Liquidity is very unstable and remains favourable on the days with the lowest activity. However, please consider that under highly turbulent market conditions, the trading volume tends to decrease significantly. The stock has a tiny market capitalisation, which usually makes its trading liquidity erratic and unpredictable. 

No other major risks have been identified.

The risk of default is high. Among the negative credit factors, we point to bleak profitability, negligible return on capital, inadequate interest coverage, and poor cash flow generation. We note resilient historical revenue growth, low margin volatility, and an favourable capital structure, among the positive credit factors. 

In highly turbulent market conditions, MGRX is exceptionally volatile. In other words, the stock will be among the worst-performers in times of extreme market volatility or shocking company news. Standalone, the worst-day losses (less than 1% of the time) will likely be critical. 

In normal market circumstances, MGRX is exceptionally volatile. Put differently, without outstanding market volatility or shocking company news, the stock's price will change quite unpredictably. The stock's losses on its worst days (less than 1-5% of the time) will range from critical to immense. 

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. 

Mangoceuticals, Inc.

$ 1.81

2

Mangoceuticals, Inc.

$ 1.81

2

Risk factor

Profitability factor

Risk / Profitability

Risk factor

Profitability factor

$ 1.81

About

About

About

About